Study Locations

The study currently has sites in the following locations:

Arizona

California

District of Columbia

Florida

Georgia

Kansas

Maryland

Minnesota

New Jersey

New York

North Carolina

Ohio

Oregon

South Carolina

Texas

Wisconsin

For additional details please visit clinicaltrials.gov where the study is registered under identifier NCT04752722. Sites are listed on

the “Contacts and Locations” section of the website.

All LEGEND study participants

may receive access to the study drug for up to 48 weeks (1 year) depending on their response to EG-70.

Thank you for considering taking part in the LEGEND study.

To assess your eligibility to participate in the study, please contact

the clinical site closest to you.